Abstract

CLC Number:

R994.11

Add to citation manager EndNote|Ris|BibTeX

URL: https://zgywjj.magtechjournal.com/EN/

https://zgywjj.magtechjournal.com/EN/Y2017/V14/I8/498

[1] 齐鲁制药有限公司.氨磺必利片(帕可)说明书(2012版)[EB/OL]. (2012-02-21)[2017-08-10].http://www.qilu-pharma.com/products_detail/productId=61.html.
[2] 吴艳琴,党丽,江沛，等. 抗精神病药物的心血管副作用及其机制的研究进展. 中国医院药学杂志,2016,26(4):327-330.
[3] Haddad P M, Anderson I M. Antipsychotic-related QTc prolongation, torsade de pointes and sudden death. Drugs[J]. 2002，62(11):1649-1671.
[4] Abdelmawla N, Mitchell A J. Sudden cardiac death and antipsychotics. Part1: risk factors and mechanisms[J]. Adv Psychiatr Treat，2006，12(1):35-44.
[5] 康燕霞，陈景旭，魏立和，等.氨磺必利片诱发Q-T间期延长1例[J].临床精神医学杂志，2012，22(1):39.
[6] 易军，胡亚荣，万其容. 氨磺必利片联合氯氮平治疗难治性精神分裂症疗效和安全性分析[J]. 精神医学杂志，2014，27(4)：278-280.
[7] 杜洁.氨磺必利片合并氯氮平治疗难治性精神分裂症临床观察[J]. 神经损伤与功能重建,2014，9(4):353-354.
[8] Isbister G K, Balit C R, Macleod D, et al.Amisulpride overdose is frequently associated with QT prolongation and torsades de pointes[J]. J Clin Psychl. 2010，30(4):391-395.
[9] Lynch M J, Woods J, George N,et al.Fatality due to amisulpride toxicity: a case report[J]. Med Sci Law，2008，48(2):173-177.
[10] 杨和增，朱华琛，曾慧，等. 氨磺必利片对精神分裂症患者心电图的影响[J].精神医学杂志,2013，26(3):196-198.
[11] 赵靖平，施慎逊.精神分裂症防治指南[M].2版,北京: 中华医学电子音像出版社,2015：125-126.
[12] Bergemann N,Kopitz J,Kress K R,et al. Plasma amisulpride levels in schizophrenia or schizoaffective disorder[J].Eur Neuropsychop-harmacol,2004,14(3):245-250.
[13] SFDA.国家食品药品监督管理局关于修订左氧氟沙星口服和注射剂说明书的通知国食药监注[2012]373号[EB/OL]. (2012-
12-31)[2017-03-25]. http://www.sda.gov.cn/WS01/CL1706/78151.html.
[14] FDA. FDA updates warnings for fluoroquinolone antibiotics[EB/OL]. (2016-07-26)[2017-05-29]. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm513183.htm.
[15] 叶月娥, 朱玲玲, 江波. 莫沙比利合用利欧致Q-T间期延长1例[J].中国现代应用药学杂志,2004,21(6):470.
[16] SFDA.药品不良反应信息通报（第55期）警惕质子泵抑制剂的骨折、低镁血症风险以及与氯吡格雷的相互作用[EB/OL]. (2013-05-31)[2017-03-25] http://www.sda.gov.cn/WS01/CL0078/80914.html.

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

[1]	LI Xinying, BAO Lei, LI Shuran, ZHAO Ronghua, SUN Jing, XIE Dan, BAO Yanyan, GUO Shanshan, CUI Xiaolan, GENG Zihan. Effect of Shufeng Jiedu Capsules on the Production of Specific Antibodies against Influenza A H1N1 Virus and the Mechanisms [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 841-850.
[2]	WANG Xinwei, PENG Yifeng, SUN Jing, JI Zuen, BAO Lei, LUO Henglei, GENG Zihan, ZHANG Hujuan, LI Shuran, ZHANG Jingsheng, GUO Shanshan, CUI Xiaolan, ZHAO Ronghua. Effect of Yiye Anti-Influenza Capsules on Pneumonia Induced by Human Coronavirus 229E Infection in Mice [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 851-855.
[3]	XIE Rui, SUN Qiyue, LI Yanying, ZHANG Jingsheng, ZHAO Ronghua, GUO Shanshan, GENG Zihan, BAO Lei, GAO Shuangrong, CUI Xiaolan, XIE Dan, SUN Jing. Impacts of Shuangshenling Granules on a Cadmium-Induced Chronic Renal Failure Model of Mice [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 856-862.
[4]	CHEN Siying, DING Xueli, LIU Shujia, ZHANG Xiaomeng, ZHANG Bing, LIN Zhijian. Modeling for Prediction of Cardiotoxicity of Chinese Herbal Medicines [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 869-875.
[5]	CAI Haili, ZHANG Xiaomeng, LIU Yadi, CHEN Lijuan, WANG Yu, ZHANG Bing. Preventive Strategies for Anthracycline-Induced Cardiotoxicity Using Traditional Chinese Medicine via Ferroptosis Regulation [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 876-882.
[6]	ZHENG Haiyun, WANG Zhigang, WU Hongwei, WANG Shaonan, WANG Bin. Identification of in vitro and in vivo Chemical Constituents of Buxin Anmian Decoction Based on UPLC-Q Exactive Orbitrap HRMS [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 883-888.
[7]	SUN Ya, WANG Xu, SUN Zhi, ZHOU Yubing. Dose Analysis of Linezolid in Severe Patients with Sepsis Complicated with Acute Kidney Injury [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 889-895.
[8]	SHI Qi, WANG Jianxin, WANG Guijie, LU Yueyang, ZHU Jiaxu, GAO Rui. Adjuvant Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease with Qingqi Huatan Pills: a Systematic Review [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 914-919.
[9]	YING Jie, XU Xiaolong, LI Bo, LIU Tengwen, LIU Qingquan. Clinical Applications of Jinhua Qinggan Granules in the Treatment of Mild Influenza: a Meta-Analysis [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 920-923.
[10]	KE Xiuqin, HAI Xuewu. 433 Cases of Adverse Drug Reactions Induced by Calcium Dobesilate Capsules [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 924-927.
[11]	LIANG Jie. 172 Cases of Adverse Drug Reactions Induced by Antineoplastic Drugs [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 928-932.
[12]	LIU Jiang, CHEN Jie, QIU Sihong, LI Na, ZHOU Ying, CHEN Yonggang, LUO Ji. Analysis of Adverse Drug Event Induced by Omacycline and Moxifloxacin Based on FAERS Databse [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 933-936.
[13]	ZHAO Mudan, ZHU Minghui, ZHANG Huan, ZHAO Yuanyang, QIN Jing. Pharmaceutical Care of a Case of Diabetic Foot Infection Caused by Proteus penneri [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 937-940.
[14]	ZHOU Yujie, HUANG Xiaojing, CHEN Mingyue, DU Pengqiang, WANG Aifeng. Two Cases of Severe Thrombocytopenia Caused by Cefoperazone Sulbactam Sodium [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 941-943.
[15]	CHEN Huabao, LIU Wei, JIANG Ting, ZHENG Lingli, LI Jing. One Case of Acute Withdrawal Syndrome Caused by Naloxone [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 944-946.